// App-Quantinova.ai

[THU0337] : LOWER-DOSE SOLUMATRIX INDOMETHACIN: COMBINED SAFETY DATA FROM TWO PHASE 3 STUDIES IN PATIENTS WITH ACUTE PAIN FOLLOWING ELECTIVE SURGERY

Researchers

Presenter

  • R. Altman

Principal Investigators

  • A. Gibofsky

  • D. Parenti

  • C. Young

Medical Centers

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

  • Hospital for Special Surgery, New York, NY.

Locations

  • United States

Companies

  • iROKO Partners Ltd

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Deep vein thrombosis

  • Constipation

  • C1 Inhibitor Deficiency

  • Venous thrombosis

  • Anxiety

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • N/A

Drug/Treatment

  • Indomethacin

  • Celecoxib

  • ALT-210

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved